Inhibition of glycogen synthase kinase-3

Methods in Molecular Biology

Volumn 468, Issue , 2008, Pages 67-75

  Ougolkov, Andrei V ^a   Billadeau, Daniel D ^a  

^a Mayo Clinic   (United States)

Author keywords

catenin; Glycogen synthase; Glycogen synthase kinase 3

Indexed keywords

ERINACEIDAE;

BETA CATENIN; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; ISOENZYME;

ANIMAL; ARTICLE; CELL LINE; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; METHODOLOGY; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; ISOENZYMES; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 58749098455     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-249-6_5     Document Type: Article

References (26)

1. PlyteSE,HughesK,Nikolakaki,PulvererBJ,Woodgett JR. (1992) Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta. 1114, 147-162.
2. Frame S, Cohen P. (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 359, 1-16.
3. Doble BW, Woodgett JR. (2003) GSIC-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 116, 1175-1186.
4. Cohen P, Frame S. (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol. 2, 769-776.
5. Cohen P, Goedert M. (2004) GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 3, 479-487.
6. Ougolkov AV, Billadeau DD. (2006) Targeting GSIC-3: a promising approach for cancer therapy? Future Oncol. 2, 91-100.
7. Dugo L, Collin M, Thiemermann C (2007) Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock. 27, 113-123.
8. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science. 272, 1023-1026.
9. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. (1999) Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem. 274, 10681-10684.
10. Ding VW, Chen RH, McCormick F. (2000) Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem. 275, 32475-32481.
11. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 406, 86-90.
12. Meijer L, Flajolet M, Greengard P. (2004) Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 25, 471-480.
13. Martinez A, Castro A, Dorronsoro I, Alonso M. (2002) Glycogen synthase kinase 3 (GSIC-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev. 22, 373-384.
14. Alonso M, Martinez A. (2004) GSIC-3 inhibitors: discoveries and developments. Curr Med Chem. 11, 755-763.
15. Stambolic V, Ruel L, Woodgett JR. (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 6, 1664-1668.
16. Ryves WJ, Harwood AJ. (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. 280, 720-725.
17. Mora A, Sabio G, Gonzalez-Polo RA, et al. (2001) Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by IC+ deprivation in cerebellar granule cells. J Neurochem. 78, 199-206.
18. Ilouz R, Kaidanovich O, Gurwitz D, EldarFinkelman H. (2002) Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem Biophys Res Commun. 295, 102-106.
19. Leclerc S, Garnier M, Hoessel R, et al. (2001) Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 276, 251-260.
20. Leost M, Schultz C, Linie A, et al. (2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem. 267, 5983-5994.
21. Smith DG, Buffet M, Fenwick AE, et al. (2001) 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSIC-3). Bioorg Med Chem Lett. 11, 635-639.
22. Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem. 77, 94-102.
23. Bhat R, Xue Y, Berg S, et al. (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem. 278, 45937-45945.
24. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ. (2002) First non-ATP competitive glycogen synthase kinase 3 beta (GSIC-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 45, 1292-1299.
25. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. (2005) Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 65, 2076-2081.
26. Zakaria S, Gomez TS, Savoy DN, et al. (2004) Differential regulation of TCR-mediated gene transcription by Vav family members. J Exp Med. 199, 429-134.